48,830
edits
Difference between revisions of "Drug toxicity"
Jump to navigation
Jump to search
→General principles
| (7 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
This article covers a few of the distinctive histomorphologic pattern and links to other articles that deal with specific organ systems. | This article covers a few of the distinctive histomorphologic pattern and links to other articles that deal with specific organ systems. | ||
=Liver drug toxicity= | =General principles= | ||
A drug/toxin reaction should be considered if there is: | |||
# Ingestion/exposure. | |||
# An appropriate temporal relation. | |||
# An empirical correlation between the drug/toxin and the pattern. | |||
#* Worsening with re-challenge. | |||
#* Improvement with removal of exposure. | |||
#* Pathologic pattern matches with toxin. | |||
#* Drug/toxin detected within individual. | |||
=Site specific= | |||
==Liver drug toxicity== | |||
*[[Drug-induced liver disease]]. | *[[Drug-induced liver disease]]. | ||
= | ==Stomach== | ||
*[[Reactive gastropathy]]. | |||
==Small bowel== | |||
*[[Small bowel diaphragm disease]]. | |||
=Specific drugs= | |||
==Sodium polystyrene sulfonate== | ==Sodium polystyrene sulfonate== | ||
:[[AKA]] ''Kayexalate'' (trade name). | :[[AKA]] ''Kayexalate'' (trade name). | ||
| Line 21: | Line 38: | ||
</gallery> | </gallery> | ||
==Proton pump inhibitor== | ==Proton pump inhibitor== | ||
{{Main|Proton pump inhibitor effect}} | {{Main|Proton pump inhibitor effect}} | ||
| Line 31: | Line 47: | ||
{{Main|Oral contraceptive pill}} | {{Main|Oral contraceptive pill}} | ||
= | ==Minocycline== | ||
*[[Minocycline associated thyroid pigmentation]]. | *[[Minocycline associated thyroid pigmentation]]. | ||
==Spironolactone== | |||
*[[Spironolactone bodies]]. | *[[Spironolactone bodies]]. | ||
=See also= | |||
*[[Basics]]. | |||
=References= | =References= | ||